HOWL

1.35

0.75% 0.01

Handel nachbörslich: 1.40 0.05 +3.70%

Werewolf Therapeutics Inc (HOWL)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$1.34

Offen:

$1.35

24-Stunden-Volumen:

345.52K

Relative Volume:

0.76

Marktkapitalisierung:

$60.16M

Einnahmen:

$19.94M

Nettoeinkommen (Verlust:

$-37.37M

KGV:

-1.2981

EPS:

-1.04

Netto-Cashflow:

$-33.38M

1W Leistung:

-6.25%

1M Leistung:

-8.78%

6M Leistung:

-44.90%

1J Leistung:

-72.56%

1-Tages-Spanne:

$1.28

$1.42

1-Wochen-Bereich:

$1.28

$1.48

52-Wochen-Spanne:

$1.28

$8.1939

Werewolf Therapeutics Inc Stock (HOWL) Company Profile

Firmenname

Werewolf Therapeutics Inc

Sektor

Healthcare (1178)

Branche

Biotechnology (678)

Telefon

617-952-0555

Adresse

200 TALCOTT AVENUE, WATERTOWN

Mitarbeiter

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

HOWL's Discussions on Twitter

Vergleichen Sie HOWL mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HOWL Werewolf Therapeutics Inc	1.35	60.16M	19.94M	-37.37M	-33.38M	-1.04
VRTX Vertex Pharmaceuticals Inc	438.40	113.67B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	683.08	74.97B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	665.68	40.50B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	277.16	35.95B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	120.88	29.63B	3.30B	-501.07M	1.03B	-2.1146

Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-04-03	Eingeleitet	JMP Securities	Mkt Outperform
2023-08-24	Eingeleitet	Wedbush	Outperform
2023-06-06	Fortgesetzt	Jefferies	Buy
2021-09-10	Eingeleitet	BofA Securities	Buy
2021-05-25	Eingeleitet	Evercore ISI	Outperform
2021-05-25	Eingeleitet	H.C. Wainwright	Buy
2021-05-25	Eingeleitet	Jefferies	Buy
2021-05-25	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Werewolf Therapeutics Inc Aktie (HOWL) Neueste Nachrichten

Jan 28, 2025

Harmony Biosciences (NASDAQ:HRMY) vs. Werewolf Therapeutics (NASDAQ:HOWL) Head to Head Review - Defense World

Jan 28, 2025

Jan 24, 2025

Barclays PLC Increases Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jan 24, 2025

Jan 19, 2025

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 13.2% in December - MarketBeat

Jan 19, 2025

Jan 17, 2025

Jane Street Group LLC Trims Holdings in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jan 17, 2025

Jan 14, 2025

Werewolf Therapeutics' SWOT analysis: stock faces challenges amid pipeline progress - Investing.com

Jan 14, 2025

Werewolf Therapeutics (NASDAQ:HOWL) Price Target Lowered to $4.00 at JMP Securities - MarketBeat

Jan 14, 2025

JMP Securities Cuts Price Target for Werewolf Therapeutics (NASDAQ:HOWL) to $4.00/Share, Down from $12.00 - HPBL

Jan 14, 2025

Werewolf Therapeutics provides business update, highlights 2025 outlook - Yahoo Finance

Jan 14, 2025

Jan 13, 2025

Werewolf Therapeutics Provides Business Update - citybiz

Jan 13, 2025

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook - GlobeNewswire

Jan 13, 2025

Werewolf Therapeutics Unveils Ambitious 2025 Pipeline Plans for Cancer Immunotherapy Programs - StockTitan

Jan 13, 2025

Jan 10, 2025

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Acquired by Geode Capital Management LLC - Defense World

Jan 10, 2025

Jan 09, 2025

Barclays PLC Buys 30,990 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jan 09, 2025

Jan 03, 2025

State Street Corp Has $1.01 Million Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jan 03, 2025

Dec 31, 2024

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 23.6% in December - MarketBeat

Dec 31, 2024

Dec 18, 2024

Werewolf Therapeutics stock hits 52-week low at $1.58 By Investing.com - Investing.com UK

Dec 18, 2024

Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Drops By 6.1% - Defense World

Dec 18, 2024

Dec 17, 2024

Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Declines By 6.1% - MarketBeat

Dec 17, 2024

Dec 14, 2024

Werewolf Therapeutics' SWOT analysis: oncology stock's potential amid clinical trials - Investing.com Australia

Dec 14, 2024

Nov 23, 2024

HC Wainwright Reaffirms “Buy” Rating for Werewolf Therapeutics (NASDAQ:HOWL) - Defense World

Nov 23, 2024

Nov 20, 2024

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference - The Manila Times

Nov 20, 2024

Nov 19, 2024

Werewolf Therapeutics stock hits 52-week low at $1.62 - Investing.com India

Nov 19, 2024

Werewolf Therapeutics stock hits 52-week low at $1.62 By Investing.com - Investing.com Canada

Nov 19, 2024

Werewolf Therapeutics stock holds buy rating amid investor concerns over cytokine therapies By Investing.com - Investing.com Canada

Nov 19, 2024

HC Wainwright Reaffirms "Buy" Rating for Werewolf Therapeutics (NASDAQ:HOWL) - MarketBeat

Nov 19, 2024

Nov 15, 2024

PFM Health Sciences, LP Increases Stake in Werewolf Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry? - Simply Wall St

Nov 14, 2024

Nov 13, 2024

Equities Analysts Set Expectations for HOWL FY2024 Earnings - MarketBeat

Nov 13, 2024

Werewolf Therapeutics' SWOT analysis: oncology biotech's stock potential amid clinical progress - Investing.com Australia

Nov 13, 2024

Nov 11, 2024

What is HC Wainwright's Forecast for HOWL Q1 Earnings? - MarketBeat

Nov 11, 2024

Nov 08, 2024

Werewolf Therapeutics reports promising trial data for cancer drug By Investing.com - Investing.com South Africa

Nov 08, 2024

Nov 07, 2024